Therefore, modified iPSCs from this study can be used as an experimental model to investigate the molecular pathogenesis of MPN patients and possibly answer the questions why the JAK2V617F and JAK2 exon 12 mutations attributed to different erythroid phenotypes. Here, JAK2 is linked to myeloproliferative disorder.